Welcome to our dedicated page for Inhibrx Biosciences SEC filings (Ticker: INBX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Inhibrx Biosciences, Inc. (NASDAQ: INBX) SEC filings page on Stock Titan provides access to the company’s public reports as filed with the U.S. Securities and Exchange Commission. Inhibrx Biosciences describes itself as a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, including ozekibart (INBRX-109) and INBRX-106, and its filings give formal detail on these programs and the company’s financial position.
Through current reports on Form 8-K, Inhibrx Biosciences furnishes information on material events such as topline results from the registrational ChonDRAgon study of ozekibart in advanced or metastatic, unresectable chondrosarcoma, interim data from expansion cohorts in colorectal cancer and Ewing sarcoma, and updates on the INBRX-106 Phase 2/3 and Phase 1/2 trials in combination with pembrolizumab. Other 8-K filings reference quarterly financial results, providing context on research and development expenses, general and administrative costs, other income or expense, and net income or loss.
Investors can also use this page to monitor how the company describes its corporate history, including its incorporation in January 2024 as a wholly owned subsidiary of Inhibrx, Inc., the sale of the INBRX-101 program to Sanofi S.A., and the distribution of Inhibrx Biosciences shares to former Inhibrx, Inc. stockholders. These structural details are reflected in the company’s explanation that its financial statements for periods prior to the spin-off are those of the former parent.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify disclosures about clinical development plans, regulatory intentions such as a planned biologics license application for ozekibart, and the company’s status as an emerging growth company. Real-time updates from EDGAR, combined with AI explanations of complex sections, allow users to review Forms 8-K and other reports more efficiently, while also tracking any insider-related filings such as Form 4 when available.
Inhibrx Biosciences reported a materially different quarter versus the prior-year period driven by the post‑spin financial position and new financing. Revenue was $1.3 million for the quarter from a Scithera license, while operating expenses were $28.7 million leading to an operating loss of $27.4 million and a net loss of $28.654 million for the three months ended June 30, 2025. The prior-year period included a $2.02 billion gain related to the Merger with the Former Parent, which produced the large net income figure in 2024.
The balance sheet shows $186.6 million cash and equivalents and total assets of $212.1 million, with accumulated deficit of $178.1 million. The company established long-term debt under a 2025 Loan Agreement with Oxford resulting in long-term debt, net of discount, of $99.3 million. Management states existing cash is sufficient to fund operations for at least 12 months. Clinically, the company continues development of ozekibart (INBRX-109) and INBRX-106, and completed full enrollment in its registration‑enabling chondrosarcoma trial in July 2025.